{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Competing risks analysis will be performed for analyzing TNT, with death as a competing event. For patients who are alive and do not receive the next line of therapy, TNT will be censored at the last study contact. Cumulative incidence function, along with 95% confidence intervals, will be reported for TNT.","groups":[{"description":"Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Cumulative Incidence Function for Time to Next Treatment (TNT)","type":"SECONDARY"}